Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR
Business segments
Q1 2026 · $630.6MThe company’s own SEC segment disclosure.
- Financial Royalty Assets$595.0M94%
- Royalty Income Other$35.6M6%
Royalty Pharma plc (RPRX) reported revenue of $674M in Q2 2026 (quarter ended June 30, 2026), up 16% from the same quarter a year earlier. That came with net income of $18M (2.7% of revenue). For the full year FY2025, revenue was $2.38B (+5.1% year on year) and net income $771M. Its largest product in 2026-Q1 was Financial Royalty Assets at $595M, 94% of the disclosed total, just ahead of Royalty Income Other at 5.6%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.